Thelin (sitaxentan sodium)
- Region
- 🇪🇺 EU
- Active substance
- sitaxentan sodium
- Company
- Pfizer Ltd.
- Status
- Withdrawn
- Therapeutic area
- Hypertension, Pulmonary
- EU approval
- Thu 10 Aug 2006
- Application
- EMEA/H/C/000679
- ATC
- C02KX03
- Official record
- www.ema.europa.eu
Indication
Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.
Regulatory milestones
No milestones recorded in the last year.
Follow Thelin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.